X4 Pharmaceuticals Inc’s latest rating changes from various analysts

NUE

X4 Pharmaceuticals Inc’s recently made public that its Chief Financial Officer Mostafa Adam S. unloaded Company’s shares for reported $46347.0 on Mar 11 ’24. In the deal valued at $0.88 per share,52,500 shares were sold. As a result of this transaction, Mostafa Adam S. now holds 0 shares worth roughly $0.0.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Ragan Paula sold 49,678 shares, generating $43,856 in total proceeds. Upon selling the shares at $0.88, the President and CEO now owns 765,068 shares.

Before that, DiBiase Mary sold 15,409 shares. X4 Pharmaceuticals Inc shares valued at $13,591 were divested by the Chief Operating Officer at a price of $0.88 per share. As a result of the transaction, DiBiase Mary now holds 291,752 shares, worth roughly $0.43 million.

B. Riley Securities downgraded its X4 Pharmaceuticals Inc [XFOR] rating to a Neutral from a a Buy in a research note published on December 12, 2023; the price target was decreased to $1 from $3. Cantor Fitzgerald began covering XFOR with “an Overweight” recommendation on December 22, 2022. Piper Sandler started covering the stock on December 12, 2022. It rated XFOR as “an Overweight”.

Price Performance Review of XFOR

On Monday, X4 Pharmaceuticals Inc [NASDAQ:XFOR] saw its stock unchanged to $1.46. Over the last five days, the stock has gained 58.13%. X4 Pharmaceuticals Inc shares have risen nearly 74.12% since the year began. Nevertheless, the stocks have risen 73.81% over the past one year. While a 52-week high of $2.58 was reached on 03/22/24, a 52-week low of $0.57 was recorded on 01/25/24. SMA at 50 days reached $0.9124, while 200 days put it at $1.1418. A total of 6.53 million shares were traded, compared to the trading of 13.26 million shares in the previous session.

Levels Of Support And Resistance For XFOR Stock

The 24-hour chart illustrates a support level at 1.3867, which if violated will result in even more drops to 1.3133. On the upside, there is a resistance level at 1.5067. A further resistance level may holdings at 1.5533. The Relative Strength Index (RSI) on the 14-day chart is 79.85, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.3893, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 8.57%. Stochastics %K at 93.62% indicates the stock is a selling.

How much short interest is there in X4 Pharmaceuticals Inc?

A steep rise in short interest was recorded in X4 Pharmaceuticals Inc stocks on Feb 29, 2024, growing by 1.6 million shares to a total of 14.4 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 12.8 million shares. There was a rise of 11.11%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 8.63% of the overall stock float, the days-to-cover ratio (short ratio) rose to 10.52.

The most recent change occurred on December 23, 2019 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $20 price target.

Most Popular